| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.8 |
| mRNA | AZD6244 | CTRPv2 | pan-cancer | AAC | -0.0069 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.028 | 0.9 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |